Demographics and clinical characteristics
| N=35 patients, 37 pregnancies, 108 visits | |
| N (%) or median (IQR) | |
| Age (years) | 29 (27–30.5) |
| Race | |
| Black/African American | 16/35 (45.7%) |
| White | 13/35 (37.1%) |
| Asian | 5/35 (14.3%) |
| Multiple/other | 1/35 (2.9%) |
| Diagnosis | |
| SLE | 33/35 (94.3%) |
| Non-SLE | 2/35 (5.7%) |
| Undifferentiated CTD | 1/35 (2.9%) |
| Linear scleroderma | 1/35 (2.9%) |
| Disease activity at each visit | |
| SLE PGA (0–3 scale) | 0.5 (0–1) |
| SLE PGA>1 | 19/90 (21.1%) visits 13/35 (37.1%) patients |
| History of lupus nephritis | 12/35 (34.3%) |
| Active lupus nephritis | 6/35 (17.1%) |
| Antiphospholipid antibody syndrome | 4/35 (11.4%) |
| Azathioprine | |
| Total daily dose (mg/day), visit | 112.5 (100–150) |
| Weight-based (mg/kg) dosage | 1.56 (1.17–1.96) |
| Hydroxychloroquine prescribed | 96/108 (88.9%) |
| Prednisone prescribed | 63/108 (58.3%) |
CTD, connective tissue disease; PGA, Physician Global Assessment.